2024³â 12¿ù 27ÀÏ ±Ý¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýÈ°

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óÇ°

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Kymeta, Intelsat and Fraunhofer IIS Successfully Demonstrate Satellite-Enabled 5G Connectivity for Mobile Communications

Kymeta and Intelsat develop future 5G technologies for satellite-based communications with mobility with Fraunhofer IIS
´º½ºÀÏÀÚ: 2021-11-10

REDMOND, WASH. & MCLEAN, VA.-- November 10, 2021 -- Kymeta, the communications company making mobile global, and Intelsat, operator of the world’s largest and most advanced integrated satellite and terrestrial network, announced today the successful demonstration of satellite-enabled 5G services on Kymeta’s electronically steered flat-panel u8 antenna using Intelsat’s global integrated satellite and terrestrial network—the first test of its kind in a mobile environment.

The demonstration, carried out by leading applied research organization Fraunhofer Institute for Integrated Circuits IIS, was held at Kymeta headquarters in partnership with Intelsat to help develop 5G satellite communication technology for mobility.

“Our participation in this early testing for the development of 5G standards over satellite is an important step in the next generation of connectivity and where 5G is heading,” said Ryan Stevenson, Ph.D., Vice President and Chief Scientist at Kymeta. “By hosting these 5G waveforms over the Kymeta™ u8 terminal, our technology continues to push the boundaries of what is possible.”

“A vocal champion for 5G standards, Intelsat provides critical leadership into release 17 of the 3GPP Non-Terrestrial Networks standards,” said Bruno Fromont, Chief Technology Officer at Intelsat. “Validating the feasibility of 5G mobile communications over satellite networks with Kymeta and Fraunhofer IIS is a significant milestone toward recognizing our future vision of an end-to-end ecosystem for a unified software-defined 5G network on a global scale.”

“Satellite-enabled 5G services have the potential to provide worldwide connectivity,” said Thomas Heyn, Group Manager at Fraunhofer Institute for Integrated Circuits IIS. “Fraunhofer IIS is focused on developing and prototyping technologies that are vital for the future, such as 5G Non-Terrestrial Networks as currently standardized in 3GPP. Our team is pleased to partner with Kymeta and Intelsat to develop groundbreaking developments in this innovation process.”

This partnership between key industry leaders and successful demonstration further validates the ability to seamlessly leverage hybrid connectivity across satellite and ground cellular networks to develop solutions that satisfy the overwhelming demand for communications on the move.



 Àüü´º½º¸ñ·ÏÀ¸·Î

PHC Live Cell Metabolic Analyzer (LiCellMo) Receives 2024 Innovation Award from The Analytical Scientist
IRIS2 lifts off as European Commission and SpaceRISE sign contract in Brussels
HistoSonics Edison¢ç Histotripsy System Treats First Pancreatic Tumor Patients in GANNON Trial
Novotech Named a Fierce CRO Award Winner in the Excellence
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)
The Next Gen of AI Awaits, GIGABYTE Sets the Benchmark for HPC at CES 2025
SpaceRISE Signs Concession Contract to Deliver Europe¡¯s IRIS©÷ Connectivity Network

 

Boomi Boosts Data Management Capabilities With Acquisition of Modern D...
Korean Robotaxi Startup Sonnet.AI Secures Level 4 Autonomous Shuttles ...
KIOXIA NVMe SSD Cryptographic Module Achieves FIPS 140-3 Level 2 Valid...
CHMP Recommends Approval of Galderma¡¯s Nemolizumab for Moderate-to-Se...
BrightPath Bio and Cellistic Announced Process Development and Manufac...
Parse Biosciences Launches Evercode Mouse BCR to Support Antibody Engi...
PDC*line Pharma Presents Primary Clinical Results From Phase I/II Tria...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚÇ¥±â 'ãæÚ¤ó¢'
´º½º±×·ì Á¤º¸ ¹Ìµð¾î ºÎ¹® »óÇ¥µî·Ï
¾ËÇÁ·Ò °è¿­ »óÇ¥, »óÇ¥µî·Ï ¿Ï·á
¾Ë¶ã°Ç¼³, »óÇ¥µî·Ï ¿Ï·á
Á¸Â÷´åÄÄ, ±Û²Ã º¯°æ »óÇ¥µî·Ï ¿Ï·á

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇÑ°è¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, Æѽº 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..